On this page
SIRT6 is the sirtuin most tightly tied to lifespan in the laboratory, and the SIRT6 longevity story is one of the most interesting in ageing biology. In mice, boosting it extends life. In humans, the evidence is thinner and messier than the supplement industry lets on. Here is what the research actually shows — mouse data, human data, and the gap between the two.
What does SIRT6 do at the molecular level?
SIRT6 is a nuclear enzyme. It uses NAD+ as fuel to modify other proteins. Most of that work happens on your chromosomes, inside the nucleus of every cell in your body.
Three enzymatic activities matter for the longevity story. SIRT6 removes acetyl tags from histones — mainly H3K9, H3K18, and H3K56. It attaches ADP-ribose to proteins like PARP1 to sharpen DNA repair. And it strips fatty-acyl groups off proteins including TNF-α, controlling their secretion [1].
Through these three chemistries, SIRT6 protects the genome from damage, silences inflammatory genes, and helps maintain telomere structure [11]. Our SIRT6 pillar article covers the biochemistry in detail, and our mechanism and structure article goes deeper still. For this article, the biochemistry is just the backdrop. The question is simpler. Does raising SIRT6 activity extend life?
How the mouse lifespan story started with Kanfi 2012
In 2012, the Cohen lab at Bar-Ilan University published a paper that changed the SIRT6 field. They engineered mice to make extra SIRT6 across the whole body from birth. Then they let those mice live out their natural lives, and compared how long they lived to their wild-type siblings.
The transgenic male mice lived about 15 per cent longer on median than controls [2]. Insulin-like growth factor signalling was reduced. Blood glucose control was preserved into old age. Body weight was lower without any diet change.
Two caveats matter here. First, the effect was only seen in males. The transgenic females did not live longer in that study. Second, these mice were engineered to overexpress SIRT6 from birth — the entire life of the animal. This is not the same as taking a supplement in middle age to raise SIRT6 activity.
Still, Kanfi 2012 remains the foundational SIRT6 longevity result. It is why the field exists as a therapeutic direction at all, and why anyone talks about SIRT6 activators today. Everything else in this article builds on it.
Does SIRT6 extend life in both sexes?
The male-only result in Kanfi 2012 was uncomfortable. It suggested SIRT6's longevity effect might depend on androgen signalling or male-specific metabolism. It also limited the case for developing SIRT6 activators for the general adult population.
Roichman 2021 answered the sex question — at least for healthspan. In a follow-up study, both male and female SIRT6-overexpressing mice showed extended healthspan, preserved gluconeogenic capacity, higher physical activity into old age, and healthier NAD+ levels [3].
Lifespan extension in females was more modest than in males, but the healthspan case is now sex-balanced. What SIRT6 does in aged animals — better metabolism, less frailty, more physical activity — happens in both sexes. That matters for translational relevance.
Why do longer-lived species make better SIRT6?
The most striking cross-species argument for SIRT6 came out of the Vera Gorbunova and Andrei Seluanov labs at the University of Rochester. Their team asked a simple question. Does SIRT6 activity vary between mammals with different lifespans?
They compared SIRT6 across 18 rodent species, from short-lived mice to long-lived beavers and naked mole-rats. SIRT6 from longer-lived species was more effective at promoting DNA double-strand break repair. Five specific amino acid substitutions accounted for most of the difference [4].
When the Rochester team engineered a "beaver-like" version of SIRT6 into mouse cells, DNA repair improved. This matters because it argues that SIRT6 is not just correlated with longevity across species — it appears to have been evolutionarily selected as a longevity gene. Nature has already tuned SIRT6 in the direction we would tune it pharmacologically. This is our SIRT6 DNA repair article in one paragraph.
Can SIRT6 reverse chromatin ageing in old mice?
Until recently, the SIRT6 story was a prevention story. Boost SIRT6 in a young animal, and it ages more slowly. Nagar 2026 asked a different and much harder question. Can you boost SIRT6 in an animal that is already old, and reverse ageing markers that are already there?
The Cohen lab and the de Cabo group at the US National Institute on Aging took normal mice, let them age naturally to about 24 months (roughly a 70-year human equivalent), then delivered extra SIRT6 to their livers. In the control group, they delivered a gene that was not expected to affect ageing [5].
The old livers that received SIRT6 showed reversal of age-related chromatin markers. Specifically, the H3K9 acetylation pattern — a chemical switch that controls whether genes are on or off — moved back toward a youthful state. Inflammatory gene expression was suppressed. Chromatin packaging tightened up.
The news cycle around this paper used the word "rewind". That framing overstates. Nagar 2026 did not show extended lifespan in already-aged mice, and it did not restore function in tissues outside the liver. What it did show is that some ageing markers in old tissue are reversible when SIRT6 is added — not that ageing itself is reversible. Ship the truth: this is a step forward, not a fountain of youth.
How SIRT6 mimics caloric restriction — the Touitou 2025 story
Caloric restriction extends life in every organism it has been tested in, from yeast to primates. SIRT6 overexpression appears to phenocopy caloric restriction — same metabolic profile, same healthspan gains. Until 2025, the mechanistic link was unclear.
Touitou 2025 identified it. In aged mouse livers, SIRT6 controls hepatic one-carbon metabolism through two arms. First, it suppresses the transcription factor Sp1, which shuts down a cystine transporter and boosts hydrogen sulfide (H2S) production. Second, it directly deacetylates a specific site on the SAM-producing enzyme Matα1, throttling excess SAM production [6].
The net effect is that aged SIRT6-overexpressing mice keep youthful levels of H2S — a gasotransmitter linked to the healthspan benefits of caloric restriction — and youthful SAM levels, without any dietary change.
This is a mouse liver mechanism, not a clinical claim. Kidney and brain did not show the same H2S rescue. But it does explain, at the metabolic level, why raising SIRT6 activity might deliver caloric-restriction-like benefits without cutting calories. That is the mechanistic thesis SIRT6 activator development now rests on.
What do the human studies actually show?
Here is where the honest reading starts. The mouse and cross-species data on SIRT6 and longevity is deep. The human data is thin, and it is often over-summarised.
Two published human datasets exist. The first is Simon 2022, which identified a rare SIRT6 variant (N308K plus A313S) enriched in a small cohort of Ashkenazi Jewish centenarians. In cell studies, the centenarian version of SIRT6 was better at repairing DNA and interacting with Lamin A [7]. The cohort was too small to reach statistical significance for the population association itself. Suggestive, not conclusive.
The second is Li 2016, a study in the Bama County longevity population in southern China. Researchers genotyped 503 rural Chinese adults for a common SIRT6 single-nucleotide polymorphism (rs350846). At the allele-frequency level, the C allele was less common in the long-lived group than in a geographically distant control group [8].
But the adjusted regression tells a different story. When the authors accounted for BMI, blood pressure, and cholesterol, the SIRT6 SNP effect washed out. Only the cardiometabolic factors remained as independent predictors of longevity. The paper's abstract says the SIRT6 variant is associated with longevity. The paper's own regression analysis says it is not, once you control for the obvious confounders.
The first prospective human intervention study on SIRT6 pathway modulation is now recruiting. It is running out of the Academy for Healthy Longevity at the National University of Singapore under Prof. Andrea B. Maier, and will follow male participants aged 50 to 80 across four visits over six months, measuring biological age, metabolic health, cognition, and vascular condition. Results are years away.
Where do SIRT6 activators actually stand today?
Kanfi 2012 is 14 years old. In 14 years, no SIRT6 activator has completed a human clinical trial. That is the honest starting point [9].
The natural-product activators — cyanidin (from black rice and blackcurrants), fucoidan (from brown seaweed), and quercetin at low concentrations — activate SIRT6 in cell assays. Fucoidan is the ingredient DoNotAge uses in its SIRT6 Activator supplement, resting on the 2025 preprint by Biashad and colleagues showing a fucoidan-based activator extended lifespan in aged wild-type mice [10]. That is preprint-level evidence in mice, not peer-reviewed and not human.
The small-molecule activators — MDL-800, MDL-811, UBCS039, SP-624, forvisirvat — are all preclinical. Some have shown effects on DNA damage in aged human chondrocytes and on chromatin marks in old mouse tissue. None has generated published human clinical trial data.
For the fucoidan-specific evidence, see our fucoidan and SIRT6 article. For the small-molecule and gene-therapy pipeline, see our SIRT6 gene therapy article. For the lifestyle levers with mechanistic support, see our how to increase SIRT6 naturally article.
What SIRT6 longevity research still can't answer
Four gaps sit at the centre of the current SIRT6 story.
The first is human lifespan or healthspan data from an interventional trial. There is none. Everything you read online about "SIRT6 extends lifespan" is a claim about mice, extrapolated to humans without evidence that the extrapolation holds.
The second is safety. SIRT6 has a nuanced role in cancer — it acts as a tumour suppressor in some contexts and can support tumour growth in others. Raising SIRT6 activity long-term in adults with sub-clinical malignancies is not without theoretical risk. Our SIRT6 and cancer article covers this in detail.
The third is sex balance in humans. Kanfi 2012 was male-only for lifespan. Roichman 2021 rebalanced healthspan but not lifespan. Whether the human effect will be sex-symmetrical is unknown, and the current NUS Singapore trial is enrolling males only for its first cohort.
The fourth is the attribution question. Some readers arrive here thinking David Sinclair discovered SIRT6 and its longevity effects. He did not. Sinclair's group has worked on SIRT1, a different sirtuin. The SIRT6 longevity work is the Haim Cohen lab at Bar-Ilan (Kanfi 2012, Roichman 2021, Nagar 2026, Touitou 2025) and the Vera Gorbunova and Andrei Seluanov labs at Rochester (Tian 2019). Correct attribution matters when you are choosing who to follow.
Bottom line
SIRT6 is one of the strongest longevity targets in ageing biology at the molecular level. The mouse work is deep. The cross-species work is compelling. The 2025 and 2026 mechanism papers give the field a coherent story for how SIRT6 phenocopies caloric restriction.
At the human level, the evidence is thin. Two small genetic studies, one prospective intervention trial recruiting now, and no completed clinical data.
If you want to follow this story, watch the NUS Singapore trial results in 2027 and 2028. Watch the peer-reviewed publication of Biashad 2025 and any follow-up human fucoidan trials. Everything else in the SIRT6 activator space today is a bet on translation. That is a class to track carefully — not one to bet on.